Market Research Logo

ActogeniX NV - Product Pipeline Review - 2015

ActogeniX NV - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘ActogeniX NV - Product Pipeline Review - 2015’, provides an overview of the ActogeniX NV’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ActogeniX NV’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ActogeniX NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ActogeniX NV’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ActogeniX NV’s pipeline products
Reasons to buy
  • Evaluate ActogeniX NV’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ActogeniX NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ActogeniX NV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ActogeniX NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ActogeniX NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ActogeniX NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


ActogeniX NV Snapshot
ActogeniX NV Overview
Key Information
Key Facts
ActogeniX NV - Research and Development Overview
Key Therapeutic Areas
ActogeniX NV - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
ActogeniX NV - Pipeline Products Glance
ActogeniX NV - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ActogeniX NV - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
ActogeniX NV - Drug Profiles
AG-013
Product Description
Mechanism of Action
R&D Progress
certolizumab pegol
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria Expressing IL-10 for IBD and Colon Cancer
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Allergic Disease
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Celiac Disease
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Type 1 Diabetes
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Type 2 Diabetes
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria Expressing Antibody for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Clostridium Difficile Enteropathy
Product Description
Mechanism of Action
R&D Progress
Genetically Engineered Bacteria for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugates for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
ActogeniX NV - Pipeline Analysis
ActogeniX NV - Pipeline Products by Target
ActogeniX NV - Pipeline Products by Route of Administration
ActogeniX NV - Pipeline Products by Molecule Type
ActogeniX NV - Pipeline Products by Mechanism of Action
ActogeniX NV - Recent Pipeline Updates
ActogeniX NV - Dormant Projects
ActogeniX NV - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
ActogeniX NV, Key Information
ActogeniX NV, Key Facts
ActogeniX NV - Pipeline by Indication, 2015
ActogeniX NV - Pipeline by Stage of Development, 2015
ActogeniX NV - Monotherapy Products in Pipeline, 2015
ActogeniX NV - Phase II, 2015
ActogeniX NV - Phase I, 2015
ActogeniX NV - Preclinical, 2015
ActogeniX NV - Discovery, 2015
ActogeniX NV - Pipeline by Target, 2015
ActogeniX NV - Pipeline by Route of Administration, 2015
ActogeniX NV - Pipeline by Molecule Type, 2015
ActogeniX NV - Pipeline Products by Mechanism of Action, 2015
ActogeniX NV - Recent Pipeline Updates, 2015
ActogeniX NV - Dormant Developmental Projects,2015
List of Figures
ActogeniX NV - Pipeline by Top 10 Indication, 2015
ActogeniX NV - Pipeline by Stage of Development, 2015
ActogeniX NV - Monotherapy Products in Pipeline, 2015
ActogeniX NV - Pipeline by Top 10 Target, 2015
ActogeniX NV - Pipeline by Top 10 Route of Administration, 2015
ActogeniX NV - Pipeline by Top 10 Molecule Type, 2015
ActogeniX NV - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report